A new £60,000-a-year Alzheimer's drug, said to be the first treatment to slow progression of the memory-robbing disease, is a ...

For more than three decades, the dominant hypothesis in Alzheimer’s disease research has rested on a single idea: that the ...

A panel of experts advising the Food and Drug Administration could on Monday recommend Eli Lilly’s experimental Alzheimer’s drug donanemab for FDA approval, a closely watched decision that could pave ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

On Monday, June 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet to discuss and vote on whether the data from Eli Lilly And Co’s (NYSE:LLY) Phase 3 Study AACI ...

The European Medicines Agency (EMA) has recommended refusal of a marketing authorization for donanemab, which targets the treatment of early Alzheimer’s disease (AD). The agency's Committee for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Donanemab has become the second anti-amyloid immunotherapy to win traditional approval from the U.S. Food and Drug Administration. The antibody, which will be marketed as Kisunla, got the official ...

(CNN) — The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease. Donanemab, made by ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. A Food and Drug Administration expert panel of advisors voted 11-0 ...

A major global report says Alzheimer's is no longer universally considered untreatable, a significant shift after decades in ...